In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss ...

If you are chasing peak performance or looking to build a powerful lower body, there’s one muscle group you’re probably not training: the adductors. Commonly re ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Use of an investigational monoclonal antibody called bimagrumab added to semaglutide produced weight loss while preserving muscle mass.

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Approval of Zusduri was based on data from the Phase III ENVISION trial, which showed a 78% complete response at three months in patients with recurrent low-grade, intermediate-risk non-muscle ...

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral resection of bladder tumors.

Discover what the mind-muscle connection really is, why it matters for building muscle and strength, and how to use it for ...

Discover how pelvic floor muscles coordinate with your diaphragm for optimal breathing and why dysfunction causes fatigue and ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.